Neuvasq Biotechnologies develops therapies that restore blood-brain barrier function and enhance neurovascular integrity for patients with severe neurological disorders, including stroke, epilepsy, and Alzheimer's disease. Their platform targets the repair of central nervous system barriers, addressing critical challenges in treating acute and chronic neurological conditions.
Funding
$24.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many severe neurological disorders, such as stroke, epilepsy, Alzheimer's disease, and vascular retinopathies, are associated with a compromised blood-brain barrier (BBB) and blood-retina barrier, hindering effective drug delivery and contributing to disease progression. Current treatments often fail to address the underlying vascular dysfunction in the central nervous system (CNS).
Solution
Neuvasq Biotechnologies is developing first-in-class Wnt surrogate antibodies that target Gpr124 and Reck to restore the integrity of the blood-brain barrier and blood-retina barrier. Their approach aims to repair central nervous system barriers, improving neurovascular function and enabling more effective treatment of neurological conditions. By targeting the Wnt signaling pathway, Neuvasq's antibodies promote the stabilization and regeneration of endothelial cells, which are critical for maintaining barrier function. This leads to reduced inflammation, improved drug penetration, and enhanced neuroprotection.
Target Audience
The primary target audience includes patients suffering from severe neurological disorders and vascular retinopathies, as well as pharmaceutical companies seeking innovative therapies to address CNS barrier dysfunction.
Features
- First-in-class Wnt surrogate antibodies targeting Gpr124 and Reck
- Designed to restore the integrity of the blood-retina and blood-brain barriers
- Potential to improve treatments for vascular retinopathies, diabetic macular edema (DME) and wet age-related macular degeneration (wAMD)
- Addresses severe neurological disorders
- Promotes the stabilization and regeneration of endothelial cells